Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.75 |
| ▸ | RARB | P10826 | 3/20 | 0.71 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.65 |
| ▸ | THRA | P10827 | 2/20 | 0.63 |
| ▸ | THRB | P10828 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8769734 | 1.00 | TP53 (0.77) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL6705357 | 1.00 | TP53 (0.77) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL15154875 | 1.00 | TP53 (0.77) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL1623628 | 1.00 | TP53 (0.77) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL18302060 | 1.00 | TP53 (0.77) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL17203727 | 0.98 | TP53 (0.74) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL8769969 | 0.94 | TP53 (0.68) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL6648277 | 0.93 | TP53 (0.73) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL18774788 | 0.93 | TP53 (0.73) | TP53TSHRPLA2G4BRARBPLA2G4A | |
| SCHEMBL534947 | 0.93 | TP53 (0.73) | TP53TSHRPLA2G4BRARBPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080114-A | Composition containing long-chain alkane for polypeptide synthesis and preparation method of polypeptide | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4673424-A1 | LIQUID PHASE PEPTIDE SUPPORT SYNTHESIS OF PEPTIDES AND PEPTIDOMIMETICS | Regeneron Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182268-A1 | LIQUID PHASE PEPTIDE SUPPORT SYNTHESIS OF PEPTIDES AND PEPTIDOMIMETICS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-111971293-B | Peptide synthesis method | JITSUBO株式会社 | 2024-07-30 | — | — | CN | disclosed |
| CN-117843715-A | Liquid phase synthesis method of melanoputan-II | 浙江工业大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117843761-A | Method for preparing melanocortin analogue cyclic peptide drug based on hydrophobic label carrier | 浙江工业大学 | 2024-04-09 | — | — | CN | disclosed |
| EP-2711370-B1 | METHOD FOR PRODUCING OLIGONUCLEOTIDES | AJINOMOTO KK (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-9670121-B2 | Diphenylmethane compound | AJINOMOTO CO., INC. (JP) | 2017-06-06 | — | — | US | disclosed |
| US-20160060198-A1 | DIPHENYLMETHANE COMPOUND | AJINOMOTO CO., INC. (JP) | 2016-03-03 | — | — | US | disclosed |
| US-9169187-B2 | Method of making peptides using diphenylmethane compound | AJINOMOTO CO., INC. (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9029528-B2 | Solution-based method of making oligonucleotides via phosphoramidite coupling | AJINOMOTO CO., INC. (JP) | 2015-05-12 | — | — | US | disclosed |
| US-20140213761-A1 | DIPHENYLMETHANE COMPOUND | AJINOMOTO CO., INC (JP) | 2014-07-31 | — | — | US | disclosed |
| US-8722934-B2 | Diphenylmethane compound | AJINOMOTO CO., INC. (JP) | 2014-05-13 | — | — | US | disclosed |
| EP-2711370-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Ajinomoto Co., Inc. (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-20120296074-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2012-11-22 | — | — | US | disclosed |
| EP-2415745-A1 | DIPHENYLMETHANE COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100249374-A1 | DIPHENYLMETHANE COMPOUND | AJINOMOTO CO., INC. (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249374-A1 | DIPHENYLMETHANE COMPOUND | CCKAR, DNPEP, QPCTL | TP53 1289/4885TSHR 2188/4885PLA2G4B 4673/4885 |
| US-20140213761-A1 | DIPHENYLMETHANE COMPOUND | CCKAR, VIP, CCKBR | TP53 2202/4885TSHR 1541/4885PLA2G4B 4856/4885 |
| US-20160060198-A1 | DIPHENYLMETHANE COMPOUND | CCKAR, VIP, CCKBR | TP53 2202/4885TSHR 1541/4885PLA2G4B 4856/4885 |
| US-20120296074-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | RNGTT, POLM, RNMT | TP53 1957/4885TSHR 1572/4885PLA2G4B 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.